Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India mulls free diagnostic services for poor as free drugs plan stalls

This article was originally published in Scrip

Executive Summary

India is evaluating plans to provide free diagnostic services for the poor, even though its ambitious proposal to roll out a free medicines scheme for patients at government health facilities is stalling amid procurement and distribution difficulties.

You may also be interested in...



Novartis Blocks Sun’s Nilotinib Plans In India

Novartis thwarts Sun’s efforts to commercialize nilotinib in India, though the Indian firm indicates that its actions are covered under a local Bolar-type provision and that it has no plans to market the anticancer while the originator's patent stands valid.

Sun’s Ilumya To Claw Into Japanese Psoriasis Market

Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.

'Covidization' Of Resources Brings Huge Disruption For TB Patients, Researchers

Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel